Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection o
How this was made
The 30-second read
Why it matters
The 68% revenue increase and raised guidance signal strong market traction, likely prompting short‑term buying interest.
Market read
The earnings beat and raised guidance provide fresh, material information for traders, making the stock a candidate for short‑term positioning.
What to watch
Higher operating expenses and net loss indicate cash burn; reliance on large contracts may pose concentration risk.
Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Third-quarter revenue grew 68%, gross margin expanded, and the company raised full-year revenue guidance, but operating expenses grew 81% and net loss widened to $13.3 million.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, three months ended September 30, 2026GAAP | $33.5M | – | 68% |
| Product revenue, three months ended September 30, 2026GAAP | $26.3M | – | – |
| Service and other revenue, three months ended September 30, 2026GAAP | $7.25M | – | 69% |
| Total cost of revenue, three months ended September 30, 2026GAAP | $12.90M | – | – |
| Cost of product revenue, three months ended September 30, 2026GAAP | $10.88M | – | – |
| Cost of service and other revenue, three months ended September 30, 2026GAAP | $2.02M | – | – |
| Gross profit, three months ended September 30, 2026GAAP | $20.64M | – | – |
| Gross margin, three months ended September 30, 2026GAAP | 61.5% | – | – |
| Research and development expense, three months ended September 30, 2026GAAP | $16.17M | – | – |
| Selling, general and administrative expense, three months ended September 30, 2026GAAP | $19.62M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $35.8M | – | 81% |
| Loss from operations, three months ended September 30, 2026GAAP | $15.1 million operating loss | – | – |
| Interest income, net, three months ended September 30, 2026GAAP | $2.17M | – | – |
| Interest expense, three months ended September 30, 2026GAAP | −$153K | – | – |
| Other expense, net, three months ended September 30, 2026GAAP | −$125K | – | – |
| Net loss before income tax, three months ended September 30, 2026GAAP | −$13.25M | – | – |
| Provision for income taxes, three months ended September 30, 2026GAAP | $94K | – | – |
| Net loss, three months ended September 30, 2026GAAP | $13.3M | – | – |
| Net loss per share, basic and diluted, three months ended September 30, 2026GAAP | $ (0.19 ) | – | – |
| Weighted-average common shares outstanding, basic and diluted, three months ended September 30, 2026GAAP | 69,106,367 | – | – |
| Total stock-based compensation expense, three months ended September 30, 2026GAAP | $3.92M | – | – |
| Total revenue, nine months ended September 30, 2026GAAP | $89.01M | – | – |
| Product revenue, nine months ended September 30, 2026GAAP | $70.91M | – | – |
| Service and other revenue, nine months ended September 30, 2026GAAP | $18.10M | – | – |
| Total cost of revenue, nine months ended September 30, 2026GAAP | $36.19M | – | – |
| Gross profit, nine months ended September 30, 2026GAAP | $52.82M | – | – |
| Research and development expense, nine months ended September 30, 2026GAAP | $43.00M | – | – |
| Selling, general and administrative expense, nine months ended September 30, 2026GAAP | $50.84M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $93.84M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$41.02M | – | – |
| Loss on remeasurement of convertible notes, nine months ended September 30, 2026GAAP | −$9.97M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$47.87M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP | $ (1.02 ) | – | – |
| Weighted-average common shares outstanding, basic and diluted, nine months ended September 30, 2026GAAP | 46,884,564 | – | – |
| Total stock-based compensation expense, nine months ended September 30, 2026GAAP | $8.66M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Instruments, three months ended September 30, 2026Driven primarily by continued growth in new instrument placements. | $8.5M | – | 50% |
| Consumables, three months ended September 30, 2026Driven primarily by strong demand for multiplex panels. | $17.8M | – | 79% |
| Services and other, three months ended September 30, 2026Driven primarily by strong demand for custom assay development services. | $7.2M | – | 69% |
| Instruments, nine months ended September 30, 2026No nine-month driver was provided. | $23.64M | – | – |
| Consumables, nine months ended September 30, 2026No nine-month driver was provided. | $47.27M | – | – |
| Services, nine months ended September 30, 2026No nine-month driver was provided. | $18.10M | – | – |
| Other revenue, nine months ended September 30, 2026No nine-month driver was provided. | — | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full year 2026 outlook
- Revenue$121 to $123 million
- NoteRepresenting growth of 64% at the midpoint of the range compared to full year 2025.
What drove it
- Biopharma customers accounted for the largest portion of revenue for the first time.
- New instrument placements supported instrument revenue growth.
- Strong demand for multiplex panels supported consumable revenue growth.
- Strong demand for custom assay development services supported services and other revenue growth.
- Gross-margin expansion was attributed to lower instrument costs, higher average selling prices for consumables, improved margins on services, and a favorable shift in product mix.
- Operating-expense growth reflected planned investments in headcount, infrastructure and R&D supplies, as well as incremental public company costs.
- UK Biobank selected Alamar to profile 80,000 samples for a study targeting neurodegenerative conditions.
- Alamar launched a strategic scientific collaboration with GSK for a large-scale 60,000-sample study.
Concerns
- Operating expenses increased 81% to $35.8 million, exceeding total revenue of $33.5 million.
- Operating loss widened to $15.1 million from an operating loss of $7.9 million.
- Net loss widened to $13.3 million from an $8.0 million net loss.
- The nine-month period included a $ (9,971 ) (in thousands) loss on remeasurement of convertible notes.
- The company identified risks including intense competition in the proteomics market, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, manufacturing complexity, and potential regulatory requirements.
What to watch
- Execution against full-year 2026 revenue guidance of $121 to $123 million.
- Whether biopharma customers remain the largest portion of revenue.
- New instrument placements and associated consumable demand.
- Realization of the cited gross-margin benefits from instrument costs, consumable pricing, services margins, and product mix.
- Spending on headcount, infrastructure, R&D supplies and public company costs.
- Transition following President Tod White’s retirement at the end of 2026 and his advisory role through June 2027.
Balance sheet and cash flow
- Cash and cash equivalents were $ 121,532 (in thousands) as of September 30, 2026, compared with $ 30,002 (in thousands) as of December 31, 2025.
- Short-term investments were $ 105,053 (in thousands) as of September 30, 2026, compared with — as of December 31, 2025.
- Restricted cash was $ 4,907 (in thousands) as of September 30, 2026 and $ 4,907 (in thousands) as of December 31, 2025.
- Cash, cash equivalents, short-term investments and restricted cash were $231.5 million as of September 30, 2026.
- Accounts receivable were $ 21,611 (in thousands), compared with $ 12,753 (in thousands) as of December 31, 2025.
- Inventory was $ 54,133 (in thousands), compared with $ 38,482 (in thousands) as of December 31, 2025.
- Total assets were $ 378,027 (in thousands), compared with $ 139,992 (in thousands) as of December 31, 2025.
- Accounts payable were $ 16,549 (in thousands), compared with $ 5,872 (in thousands) as of December 31, 2025.
- Total liabilities were $ 74,323 (in thousands), compared with $ 63,950 (in thousands) as of December 31, 2025.
- Term debt was — as of September 30, 2026, compared with $ 9,810 (in thousands) as of December 31, 2025.
- Total stockholders’ equity (deficit) was $ 303,704 (in thousands), compared with $ (158,954 ) (in thousands) as of December 31, 2025.
Analysis
Alamar reported $33.5 million of third-quarter revenue, up 68% from $19.9 million in the corresponding prior-year period. Growth was broad across the reported revenue sources: instrument revenue grew 50% to $8.5 million, consumable revenue grew 79% to $17.8 million, and services and other revenue grew 69% to $7.2 million. Management said biopharma customers accounted for the largest portion of revenue for the first time, while new instrument placements, multiplex-panel demand, and custom assay development services were the stated revenue drivers.
The revenue mix supported improved gross profitability. Gross margin increased to 61.5% from 59.7%, which the company attributed to lower instrument costs, higher average selling prices for consumables, improved services margins, and a favorable product-mix shift. Gross profit was $ 20,644 (in thousands), compared with $ 11,897 (in thousands) in the prior-year quarter. The nine-month results showed $ 89,007 (in thousands) in total revenue and $ 52,819 (in thousands) in gross profit.
Investment spending remained substantial. Total operating expenses rose 81% to $35.8 million, driven by planned headcount, infrastructure and R&D-supply investments and incremental public company costs. Research and development expense was $ 16,167 (in thousands), selling, general and administrative expense was $ 19,616 (in thousands), and total stock-based compensation expense was $ 3,916 (in thousands). As a result, operating loss widened to $15.1 million from $7.9 million and net loss widened to $13.3 million from $8.0 million.
Liquidity was supported by $231.5 million of cash, cash equivalents, short-term investments and restricted cash as of September 30, 2026. The balance sheet reported no term debt at September 30, 2026, versus $ 9,810 (in thousands) at December 31, 2025. The company raised full-year 2026 revenue guidance to $121 to $123 million from previous expectations of $116 to $120 million. Operationally, investors will focus on execution against that range, continued instrument placements and consumable demand, the expansion of biopharma revenue, and the company’s ability to sustain gross-margin improvement while managing operating-expense growth.
The company also announced that President Tod White will retire at the end of 2026 and will serve as an advisor through June 2027. Commercial developments included selection by UK Biobank to profile 80,000 samples and a strategic scientific collaboration with GSK for a 60,000-sample study. These developments accompany the company’s stated demand momentum but do not alter the reported operating loss and continued investment profile.
Management, verbatim
Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time.
Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences
Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale.
Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences
It has been a privilege to work alongside this exceptional team. Their talent, dedication, and belief in what precision proteomics can do to improve human health have driven everything we have accomplished. Alamar is well positioned to lead the next era of proteomics, and I have never been more confident in the company’s future.
Tod White, president
Not in the filing
stated, not guessed- Non-GAAP revenue, gross margin, operating income or loss, net income or loss, and EPS were not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Capital expenditures were not reported.
- Share repurchases and dividends were not reported.
- A tax-rate guidance figure was not reported.
- Gross-margin guidance and operating-expense guidance were not reported.
- Prior-quarter comparisons were not reported for the financial metrics.
- A prior-release outlook section was not provided for formal actual-versus-prior-guidance comparison.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Alamar Biosciences, a Nasdaq‑listed precision proteomics company, filed its Q3 2026 8‑K with financial results and updated guidance.
Ticker impact
issued guidance raising full-year 2026 revenue to $121‑123 million
likely upward pressure as the market prices in the raised guidance
The strong top‑line growth and higher guidance suggest improved future cash flow, which should support the stock price in the near term.
Market effects
Highlights growing demand for precision proteomics, potentially benefiting peers in biotech and diagnostics.
Positive for US biotech sector; may boost investor sentiment toward small‑cap life‑science stocks.
Limited to niche proteomics market, no broad macro impact.
Counterpoint
The raised guidance may already be priced in; execution risk on new collaborations could temper upside.
Key entities
- companyAlamar Biosciences, Inc.
Nasdaq‑listed proteomics firm reporting Q3 results and raised 2026 revenue guidance.
- partnerGSK
Collaborating with Alamar on a 60,000‑sample study.
